Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in...
Vaccine
Bioma Probiotics Launches Science-Backed Gut Health Formula for Women’s Natural Weight Loss
Discover how Bioma Probiotics supports weight loss, balances gut health, and helps women reduce bloating, boost energy, and improve digestion...
CHO Plus Enters into Project Agreement with BARDA’s BioMaP Consortium to Develop High Productivity Cell Lines for Filovirus Monoclonal Antibody Production
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Privately held CHO Plus, Inc. announced today a project agreement...
Phase 1 Clinical Ttrial of HIV Vaccine Starts in Africa to Evaluate Immune Responses to Highly Networked HIV T-Cell Epitopes
Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given....
Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines
The MOU intends to combine proprietary mRNA vaccine platform of HelixNano with proprietary Microneedle array (MNA) delivery platform of Medicus.Philadelphia,...
Desert Oasis Healthcare Offered Free Tdap Vaccines for Palm Springs Unified Students Ahead of Back-to-School Season
DOHC Helps PSUSD Students Get Ready for School with Free Vaccines PALM SPRINGS, CA / ACCESS Newswire / August 1,...
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)Updates 2025 projected...
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trialActively...
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of...
The Global Biologics Outsourcing Market Accounted for $20.7B in 2024 Driven by Rising Demand for Modality-Specific, End-to-End CDMO Capabilities, Finds Alira Health
Annual, signature publication provides updated analysis of global CDMO trends, market shifts, and the accelerating impact of advanced therapiesFRAMINGHAM, Mass.,...
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped...
How Cell-Free mRNA Templates Support Faster Research with High-Quality and Quick Turnaround, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how integrated solutions — from vector design to cell-free in vitro transcription (IVT) template preparation —...
IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025...
BriaCell Awarded New Zealand Patent for its Whole Cell Technology
PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT)...
IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025
LAWRENCEVILLE, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its...
Branded Legacy, Inc. Signs Letter of Intent to Acquire Bio-Legacy Evaluative Group, Advancing Innovations in Intranasal Drug Delivery
Strategic Acquisition Positions Branded Legacy to Enter the Growing Naloxone and Vaccine Markets, Enhancing Shareholder Value; Leadership Transition Planned with...
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
TILsRx platform designed to overcome immune suppression and T cell exhaustion to activate tumor-infiltrating lymphocytes (TILs) Multivalent technology enables simultaneous...
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth –– ARCALYST 2025 expected net...
Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)
- Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into...
IMUNON Announces Stock Dividend Boosting Shareholder Value
Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July...